Access Reminder for Bruker Investor Webinar on May 17, 2024
May 16 2024 - 10:34AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) will host an Investor Webinar
from 10 am to about 12 noon Eastern Daylight Time (EDT) tomorrow
May 17, 2024, to provide additional insights into its three recent
acquisitions of Chemspeed, ELITech, and of the NanoString business.
Bruker also expects to provide an update to its medium-term
financial outlook.
The Investor Webinar will include presentations by CEO Frank H.
Laukien, CFO Gerald Herman, and by the leaders of these three new
Bruker businesses, Bernd Gleixner, Christoph Gauer and Mark Munch.
The presentations will followed by a live Q&A session for
analysts and investors.
The link to the Investor Webinar and dial-in option info will be
available in the Events & Presentations section of the
Company’s Investor Relations website at https://ir.bruker.com. A
replay will be available on Bruker’s Investor Relations website
after the conclusion of the event.
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516258602/en/
Justin Ward Sr. Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Nov 2023 to Nov 2024